Compare Stocks

→ Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHL Achilles Therapeutics	$0.82 +0.1%	$1.13	$0.74 ▼ $1.76	$32.50M	1.09	693,473 shs	153,544 shs
AXLA Axcella Health	$0.40 -8.9%	$0.84	$0.34 ▼ $41.25	$1.18M	0.46	267,009 shs	6,700 shs
CRDL Cardiol Therapeutics	$1.70 -2.9%	$1.62	$0.51 ▼ $2.17	$115.89M	0.95	357,131 shs	40,030 shs
TCRX TScan Therapeutics	$6.90 +2.2%	$7.02	$1.62 ▼ $9.00	$330.37M	0.9	184,578 shs	138,721 shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHL Achilles Therapeutics	+2.72%	+0.54%	-25.09%	-1.79%	-8.10%
AXLA Axcella Health	0.00%	0.00%	0.00%	0.00%	-95.96%
CRDL Cardiol Therapeutics	+1.74%	-6.42%	+16.67%	+65.09%	+239.67%
TCRX TScan Therapeutics	-5.33%	-6.64%	-1.17%	+28.33%	+221.43%

Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (Ad)

Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.

Learn More Now

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHL Achilles Therapeutics	1.5838 of 5 stars	3.0	3.0	0.0	0.0	1.6	0.8	1.3
AXLA Axcella Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	1.2443 of 5 stars	3.5	3.0	0.0	0.0	1.1	0.0	0.6
TCRX TScan Therapeutics	1.7823 of 5 stars	3.5	3.0	0.0	0.0	2.4	1.7	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHL Achilles Therapeutics	2.00	Hold	$4.00	390.80% Upside
AXLA Axcella Health	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	3.00	Buy	$3.00	76.47% Upside
TCRX TScan Therapeutics	3.00	Buy	$12.50	81.16% Upside

Current Analyst Ratings

Latest TCRX, ACHL, CRDL, and AXLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/17/2024	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$10.00
4/5/2024	ACHL Achilles Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $6.00
4/5/2024	ACHL Achilles Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$8.00 ➝ $2.00
3/7/2024	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
3/6/2024	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$9.00 ➝ $10.00
2/26/2024	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$9.00
2/1/2024	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$9.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	$3.49 per share	N/A
AXLA Axcella Health	N/A	N/A	N/A	N/A	$1.42 per share	N/A
CRDL Cardiol Therapeutics	$60K	1,931.48	N/A	N/A	$0.32 per share	5.31
TCRX TScan Therapeutics	$21.05M	15.69	N/A	N/A	$3.15 per share	2.19

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHL Achilles Therapeutics	-$69.67M	-$1.74	N/A	N/A	N/A	N/A	-42.55%	-37.54%	5/8/2024 (Estimated)
AXLA Axcella Health	-$81.19M	-$19.25	N/A	∞	N/A	N/A	N/A	-259.91%	N/A
CRDL Cardiol Therapeutics	-$20.84M	-$0.33	N/A	N/A	N/A	N/A	-76.18%	-62.52%	5/20/2024 (Estimated)
TCRX TScan Therapeutics	-$89.22M	-$1.89	N/A	N/A	N/A	-423.86%	-60.65%	-33.86%	5/8/2024 (Estimated)

Latest TCRX, ACHL, CRDL, and AXLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/6/2024	12/31/2023	TCRX TScan Therapeutics	-$0.29	-$0.21	+$0.08	-$0.21	$2.94 million	$7.21 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	N/A
AXLA Axcella Health	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHL Achilles Therapeutics	N/A	8.57	8.57
AXLA Axcella Health	N/A	0.80	0.80
CRDL Cardiol Therapeutics	0.01	4.36	4.36
TCRX TScan Therapeutics	0.18	6.51	6.51

Ownership

Institutional Ownership

Company	Institutional Ownership
ACHL Achilles Therapeutics	56.38%
AXLA Axcella Health	65.07%
CRDL Cardiol Therapeutics	12.49%
TCRX TScan Therapeutics	82.83%

Insider Ownership

Company	Insider Ownership
ACHL Achilles Therapeutics	5.38%
AXLA Axcella Health	2.20%
CRDL Cardiol Therapeutics	5.25%
TCRX TScan Therapeutics	8.27%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHL Achilles Therapeutics	234	39.88 million	37.73 million	Not Optionable
AXLA Axcella Health	11	2.95 million	2.88 million	Optionable
CRDL Cardiol Therapeutics	N/A	68.17 million	64.59 million	Not Optionable
TCRX TScan Therapeutics	154	47.88 million	43.92 million	Not Optionable

TCRX, ACHL, CRDL, and AXLA Headlines

Source	Headline
	Wedbush Comments on TScan Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:TCRX) marketbeat.com - April 18 at 6:31 AM
	TScan launches $125 million public stock offering investing.com - April 18 at 12:57 AM
	TScan Therapeutics (NASDAQ:TCRX) Stock Rating Reaffirmed by Wedbush marketbeat.com - April 17 at 3:51 PM
	TScan Therapeutics, Inc.: TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities finanznachrichten.de - April 17 at 9:55 AM
	TScan Therapeutics Announces Pricing Of Public Offering - Quick Facts markets.businessinsider.com - April 17 at 9:55 AM
	TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering finance.yahoo.com - April 17 at 9:55 AM
	TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering finance.yahoo.com - April 16 at 7:19 PM
	TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities globenewswire.com - April 16 at 4:01 PM
	TScan Therapeutics Appoints Chrystal Louis As Chief Medical Officer - Quick Facts markets.businessinsider.com - April 8 at 8:42 AM
	TScan Therapeutics Appoints Louis As CMO markets.businessinsider.com - April 8 at 8:42 AM
	TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer finance.yahoo.com - April 8 at 8:42 AM
	TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D. globenewswire.com - April 8 at 8:00 AM
	TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference globenewswire.com - April 2 at 7:00 AM
	Hedge funds investors control 50% of TScan Therapeutics, Inc. (NASDAQ:TCRX) and were rewarded last week after stock increased 16% finance.yahoo.com - March 26 at 11:06 PM
	Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With investorplace.com - March 17 at 2:58 PM
	Positive Outlook for TScan Therapeutics with Promising Clinical Trials and Strong Financial Position markets.businessinsider.com - March 11 at 1:18 AM
	Strong Buy Rating for TScan Therapeutics Amidst Promising Drug Developments and Financial Health markets.businessinsider.com - March 7 at 6:17 PM
	Buy Rating Affirmed for TScan Therapeutics Following Promising Phase 1 Results markets.businessinsider.com - March 7 at 6:17 PM
	TScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical Pipeline finance.yahoo.com - March 7 at 6:17 PM
	TScan Therapeutics: Q4 Earnings Insights benzinga.com - March 6 at 5:14 PM
	TCRX Stock Earnings: TScan Therapeutics Beats EPS, Beats Revenue for Q4 2023 investorplace.com - March 6 at 3:01 PM
	TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates zacks.com - March 6 at 9:16 AM
	TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update globenewswire.com - March 6 at 7:00 AM
	TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference globenewswire.com - February 28 at 7:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Achilles Therapeutics

NASDAQ:ACHL

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Axcella Health

NASDAQ:AXLA

Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Cardiol Therapeutics

NASDAQ:CRDL

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

TScan Therapeutics

NASDAQ:TCRX

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial